Healthy Q2 and H1; resulting in consecutive guidance upgrade
04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."
Pages
63
Language
English
Published on
04/08/22
You may also be interested by these reports :
04/02/26
The FY25 performance was in line with expectations, with 7.6% revenue growth and 170bps margin expansion driven by BPS strength, improved mix, and ...
03/02/26
Sartorius Stedim’s operations recovered well in FY25, driven primarily by high-margin consumables. Positive volume and mix effects expanded ...
03/02/26
Demant’s 2025 figures slightly exceeded estimates, driven by growth in Hearing Care and Diagnostics, particularly towards the year-end. However, ...
28/01/26
Getinge reported a soft Q4, with net sales and adjusted EBITA missing expectations and organic growth slowing to 1.2%. Order momentum also eased, ...